Literature DB >> 8726018

In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

C J Bacchi1, R Brun, S L Croft, K Alicea, Y Bühler.   

Abstract

A series of novel aromatic derivatives based on the structure of methylglyoxal bis(guanylhydrazone) (MGBG) was examined for trypanocidal activities in human and veterinary trypanosomes of African origin. One agent, CGP 40215A, a bicyclic analog of MGBG which also resembles the diamidines diminazene (Berenil) and pentamidine, was curative of infections by 19 isolates of Trypanosoma brucei subspecies as well as a Trypanosoma congolense isolate. Several of these isolates were resistant to standard trypanocides. Curative doses were < or = 25 mg/kg of body weight/day for 3 days in these acute laboratory model infections. In addition, CGP 40215A also cured a model central nervous system infection in combination with the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine (DFMO; Ornidyl, eflornithine). Curative combinations were 14 days of oral 2% DFMO (approximately 5 g/kg/day) plus 5, 10, or 25 mg/kg/day for 3 or 7 days given by intraperitoneal injection or with a miniosmotic pump. Combinations were most effective if CGP 40215A was given in the second half or at the end of the DFMO regimen. MGBG has modest activity as an inhibitor of trypanosome S-adenosylmethionine decarboxylase (50% inhibitory concentration [IC50]. 130 microM), while CGP 40215A was a more active inhibitor (IC50, 20 microM). Preincubation of trypanosomes with CGP 40215A for 1 h caused a reduction in spermidine content (36%) and an increase in putrescine content (20%), indicating that one possible mechanism of its action may be inhibition of polyamine biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726018      PMCID: PMC163348          DOI: 10.1128/AAC.40.6.1448

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya.

Authors:  J D Bales; S M Harrison; D L Mbwabi; P J Schecter
Journal:  Ann Trop Med Parasitol       Date:  1989-08

2.  Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense.

Authors:  C J Bacchi; H C Nathan; T Livingston; G Valladares; M Saric; P D Sayer; A R Njogu; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part I. Review of literature and description of the study areas.

Authors:  D Mehlitz; U Brinkmann; L Haller
Journal:  Tropenmed Parasitol       Date:  1981-09

4.  The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis.

Authors:  F W Jennings
Journal:  Bull Soc Pathol Exot Filiales       Date:  1988

5.  Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.

Authors:  C J Bacchi; H C Nathan; A B Clarkson; E J Bienen; A J Bitonti; P P McCann; A Sjoerdsma
Journal:  Am J Trop Med Hyg       Date:  1987-01       Impact factor: 2.345

6.  New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin.

Authors:  A B Clarkson; E J Bienen; C J Bacchi; P P McCann; H C Nathan; S H Hutner; A Sjoerdsma
Journal:  Am J Trop Med Hyg       Date:  1984-11       Impact factor: 2.345

7.  Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.

Authors:  F W Jennings; G D Gray
Journal:  Contrib Microbiol Immunol       Date:  1983

8.  Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.

Authors:  A J Bitonti; C J Bacchi; P P McCann; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1985-05-15       Impact factor: 5.858

9.  Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase.

Authors:  A J Bitonti; T L Byers; T L Bush; P J Casara; C J Bacchi; A B Clarkson; P P McCann; A Sjoerdsma
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 10.  Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy.

Authors:  A E Pegg
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

View more
  21 in total

1.  Binding-linked protonation of a DNA minor-groove agent.

Authors:  Binh Nguyen; Jaroslav Stanek; W David Wilson
Journal:  Biophys J       Date:  2005-11-18       Impact factor: 4.033

2.  Validation of spermidine synthase as a drug target in African trypanosomes.

Authors:  Martin C Taylor; Harparkash Kaur; Bernard Blessington; John M Kelly; Shane R Wilkinson
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

3.  Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-noraristeromycin derivatives with variations in the cyclopentyl ring substituents.

Authors:  K L Seley; S W Schneller; D Rattendi; S Lane; C J Bacchi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

Authors:  R Brun; Y Bühler; U Sandmeier; R Kaminsky; C J Bacchi; D Rattendi; S Lane; S L Croft; D Snowdon; V Yardley; G Caravatti; J Frei; J Stanek; H Mett
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase.

Authors:  Oleg A Volkov; Anthony J Brockway; Stephen A Wring; Michael Peel; Zhe Chen; Margaret A Phillips; Jef K De Brabander
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

6.  Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.

Authors:  Oleg A Volkov; Casey C Cosner; Anthony J Brockway; Martin Kramer; Michael Booker; Shihua Zhong; Ariel Ketcherside; Shuguang Wei; Jamie Longgood; Melissa McCoy; Thomas E Richardson; Stephen A Wring; Michael Peel; Jeffrey D Klinger; Bruce A Posner; Jef K De Brabander; Margaret A Phillips
Journal:  ACS Infect Dis       Date:  2017-04-07       Impact factor: 5.084

7.  Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.

Authors:  Robert H Barker; Hanlan Liu; Bradford Hirth; Cassandra A Celatka; Richard Fitzpatrick; Yibin Xiang; Erin K Willert; Margaret A Phillips; Marcel Kaiser; Cyrus J Bacchi; Aixa Rodriguez; Nigel Yarlett; Jeffrey D Klinger; Edmund Sybertz
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

8.  Trypanocidal activity of 8-methyl-5'-{[(Z)-4-aminobut-2-enyl]-(methylamino)}adenosine (Genz-644131), an adenosylmethionine decarboxylase inhibitor.

Authors:  Cyrus J Bacchi; Robert H Barker; Aixa Rodriguez; Bradford Hirth; Donna Rattendi; Nigel Yarlett; Clifford L Hendrick; Edmund Sybertz
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  Product feedback regulation implicated in translational control of the Trypanosoma brucei S-adenosylmethionine decarboxylase regulatory subunit prozyme.

Authors:  Yanjing Xiao; Suong Nguyen; Sok Ho Kim; Oleg A Volkov; Benjamin P Tu; Margaret A Phillips
Journal:  Mol Microbiol       Date:  2013-05-02       Impact factor: 3.501

10.  Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.

Authors:  Tana Bowling; Luke Mercer; Robert Don; Robert Jacobs; Bakela Nare
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-03-03       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.